Ascendis Pharma reported a strong third quarter of 2026 with product revenue rising 89% year-over-year to €366 million, led by significant growth in sales of YORVIPATH, SKYTROFA, and YUVIWEL. The company received positive EU regulatory opinions for TransCon CNP, with a final decision expected in Q4 2026 and a planned EU launch in Germany in Q1 2027. Clinical data showed promising results for treating achondroplasia in infants, and multiple clinical trials are underway or planned. Ascendis also posted an operating profit of €125 million and net profit of €74 million, reflecting improved financial health and ongoing global commercial expansion.
Ascendis Pharma's stock price on Pluang stands at USD 263.99, up 1.82% as of Nov 12, 2026 19:22 WIB, reflecting steady investor interest following the company's strong Q3 financial results and positive regulatory developments. The company holds a market cap of $17.03 billion and a 52-week high of $277.18, indicating robust market confidence amid its ongoing global expansion and clinical progress.
